Cure Parkinson’s and Alzheimer’s Research UK announce a partnership
Cure Parkinson’s and Alzheimer’s Research UK are working on an initiative that could pave the way for innovative neurodegenerative treatments. There is a growing recognition that tackling neurodegenerative diseases could benefit from a collaborative, cross-disease approach. We are recognising the overlap in underlying biological...
Learn more
Improving Parkinson’s Trials: A Delphi Study
Under the visionary leadership of Dr Camille Carroll at the University of Plymouth, Cure Parkinson’s has been supporting an exploratory study at the University of Plymouth to understand the best way of improving clinical trials in order to speed up the development of new treatments…
Further funding announced for clinical studies and data investigation
After a year of disruption, clinical research has now restarted and lab-based research is getting back on track. Cure Parkinson’s is delighted to report that it is investing significant funds into research in the first quarter of 2021.
An important ruling for aducanumab
On the 7th June, the US FDA held a special meeting and approved an experimental drug called aducanumab for the treatment of Alzheimer’s. This decision represents a major milestone for neurodegenerative research.
Cure Parkinson’s funds new nerve growth factors for Parkinson’s
Nerve growth or neurotrophic factors such as CDNF and GDNF are proteins that support neurons and encourage their growth and survival during development. There has been considerable preclinical research exploring their potential use in Parkinson’s
The exenatide phase 3 study protocol
Researchers conducting the phase 3 ‘Exenatide PD3’ clinical trial have published the protocol of the study, which outlines the details of the trial. Cure Parkinson’s is supporting two sub-studies within the phase 3 trial.